RELB antibody (AA 400-579)

Catalog No. ABIN7172594

Product Details anti-RELB Antibody

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Binding Specificity: AA 400-579

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This RELB antibody is un-conjugated

Application: Western Blotting (WB), ELISA, Immunofluorescence (IF)

Cross-Reactivity: Human, Mouse

Purification: >95%, Protein G purified

Immunogen: Recombinant Human Transcription factor RelB protein (400-579AA)

Isotype: IgG

Application Details

Application Notes: Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:500,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, pH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for RELB

Target: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Alternative Name: RELB (RELB Products)

Synonyms: shep antibody, I-REL antibody, IREL antibody, REL-B antibody, XRelB antibody, relb-A antibody, GC-rich antibody, avian reticuloendotheliosis viral (v-rel) oncogene related B antibody, RELB proto-oncogene, NF-kB subunit antibody, v-rel avian reticuloendotheliosis viral oncogene homolog B S homeolog antibody, Relb antibody, RELB antibody, relb.S antibody

Background:

Background: NF-kappa-B is a pleiotropic transcription factor which is present in almost all cell types and is involved in many biological processed such as inflammation, immunity, differentiation, cell growth, tumorigenesis and apoptosis. NF-kappa-B is a homo- or heterodimeric complex formed by the Rel-like domain-containing proteins RELA/p65, RELB, NFKB1/p105, NFKB1/p50, REL and NFKB2/p52. The dimers bind at kappa-B sites in the DNA of their target genes and the individual dimers have distinct preferences for different kappa-B sites that they can bind with distinguishable affinity and specificity. Different dimer combinations act as transcriptional activators or repressors, respectively. NF-kappa-B is controlled by various mechanisms of post-translational modification and subcellular compartmentalization as well as by interactions with other cofactors or corepressors. NF-kappa-B complexes are held in the cytoplasm in an inactive state complexed with members of the NF-kappa-B inhibitor (I-kappa-B) family. In a conventional activation pathway, I-kappa-B is phosphorylated by I-kappa-B kinases (IKKs) in response to different activators, subsequently degraded thus liberating the active NF-kappa-B complex which translocates to the nucleus. NF-kappa-B heterodimeric RelB-p50 and RelB-p52 complexes are transcriptional activators. RELB neither associates with DNA nor with RELA/p65 or REL. Stimulates promoter activity in the presence of NFKB2/p49. As a member of the NUPR1/RELB/IER3 survival pathway, may provide pancreatic ductal adenocarcinoma with remarkable resistance to cell stress, such as starvation or gemcitabine treatment. Regulates the circadian clock by repressing the transcriptional activator activity of the CLOCK-ARNTL/BMAL1 heterodimer in a CRY1/CRY2 independent manner. Increased repression of the heterodimer is seen in the presence of NFKB2/p52.

Aliases: I REL antibody, I-Rel antibody, IREL antibody, Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody, relB antibody, RELB_HUMAN antibody, Reticuloendotheliosis viral oncogene homolog B antibody, Transcription factor Rel B antibody, Transcription factor RelB antibody, v rel avian reticuloendotheliosis viral oncogene homolog B antibody, v rel reticuloendotheliosis viral oncogene homolog B antibody

UniProt: Q01201

Pathways: NF-kappaB Signaling, RTK Signaling